MedTrace Logo

Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT

NCT05084027 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-10-27

No results posted yet for this study

Summary

venetoclax combining with fludarabine and melphalan as conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for older patients with hematologic malignancies

Conditions

  • Hematologic Malignancy
  • Older Patients
  • Allogeneic Hematopoietic Stem Cell Transplantation

Interventions

COMBINATION_PRODUCT

venetoclax combining with fludarabine and melphalan

Venetoclax 400mg/day，oral，day-8～day-2; Fludarabine, 30mg/m2/day，intravenous，d-7～d-3；Melphalan, 140mg/ m2/d，intravenous，day-2

Sponsors & Collaborators

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER

  • Zhejiang Provincial People's Hospital

    collaborator OTHER

  • The Affiliated People's Hospital of Ningbo University

    collaborator OTHER_GOV

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Ningbo Hospital of Zhejiang University

    collaborator UNKNOWN

  • The First Affiliated Hospital of Zhejiang Chinese Medical University

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Principal Investigators

  • Yi Luo, M.D. · First Affilaated Hospital of Medical School of Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-07
Primary Completion
2022-09-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05084027 on ClinicalTrials.gov